This suggests that unlike in normal cells where CDK4/6 can rapidly compensate for pharmacologic inhibition of CDK2 to drive ongoing proliferation (18), this is not the case in CCNE1-amplified cancers. This evidence concerns the gene CDK2 and cancer.